-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Navidea Biopharmaceuticals, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2013 to 2022.
- Navidea Biopharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2023 was -$2.26M, a 60.5% increase year-over-year.
- Navidea Biopharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$15.2M, a 29.6% decline from 2021.
- Navidea Biopharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$11.7M, a 9.26% decline from 2020.
- Navidea Biopharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$10.7M, a 2.04% increase from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)